Metagenomi, Inc. Common Stock Cash Flow Conversion Efficiency
Metagenomi, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Metagenomi, Inc. Common Stock (MGX) has a cash flow conversion efficiency ratio of -0.173x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.51 Million) by net assets ($112.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Metagenomi, Inc. Common Stock (2021–2025)
Cash flow conversion efficiency of Metagenomi, Inc. Common Stock from 2021 to 2025. This chart illustrates how Metagenomi, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Metagenomi, Inc. Common Stock for real-time trading data and today's change.
Metagenomi, Inc. Common Stock Cash Flow Conversion Ratio Explained
Metagenomi, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Metagenomi, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Metagenomi, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see MGX company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CL Educate Limited
NSE:CLEDUCATE
|
0.301x |
|
Intrum Justitia AB
ST:INTRUM
|
0.059x |
|
Ezwelfare Co Ltd
KQ:090850
|
0.020x |
|
Apollo Power Ltd
TA:APLP
|
-0.100x |
|
Cable One Inc
NYSE:CABO
|
0.370x |
|
New Advanced Electronics Technologies Co Ltd
TWO:3465
|
-0.107x |
|
Bumi Teknokultura Unggul Tbk
JK:BTEK
|
-0.028x |
|
Partnera Oyj
HE:PARTNE1
|
0.030x |
Annual Cash Flow Conversion Efficiency for Metagenomi, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Metagenomi, Inc. Common Stock from 2021 to 2025. Review Metagenomi, Inc. Common Stock free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $158.60 Million | $-88.89 Million | -0.560x | -20.69% |
| 2024-09-30 | $234.86 Million | $-109.07 Million | -0.464x | -168.89% |
| 2023-09-30 | $-135.58 Million | $-91.41 Million | 0.674x | +268.81% |
| 2022-09-30 | $-74.43 Million | $29.72 Million | -0.399x | +46.42% |
| 2021-09-30 | $-32.54 Million | $24.26 Million | -0.745x | -- |
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for … Read more